Although further studies that would evaluate this concordance with fluorescence in situ hybridization and immunohistochemistry methods are needed, our findings suggest that the 2013 ASCO/CAP HER2 testing criterion for breast cancer is applicable for determination of genetic changes in CRC. Here, ERBB2 is linked to breast cancer.